Digital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone–secreting pituitary tumors
European Journal of Endocrinology · 2025
DOI: 10.1093/ejendo/lvae170 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Endocrinology, 2025. Verfasst von Claudia Campana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI), University of Genova, 16132 Genova, Italy. Hauptthemen laut MEDLINE: Receptors, Somatostatin, Growth Hormone-Secreting Pituitary Adenoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Immunohistochemistry (IHC) of somatostatin receptor subtype 2 can predict response to first-generation somatostatin receptor ligands (fg-SRLs) in acromegaly. Recently, we validated an open-source digital image analysis (DIA) to quantify somatostatin receptor subtype 2 (SSTR2) expression. We aimed to validate the DIA also on somatostatin receptor subtype 5 (SSTR5) in a new cohort of growth hormone (GH)-secreting pituitary tumors, with IHC performed in a different laboratory, and to correlate fg-SRL response with SSTs expression. Somatostatin receptor subtype 2 and SSTR5 were assessed in 42 GH-secreting pituitary tumors, using a semiquantitative immunoreactivity score (IRS) and the DIA by use of the open-access software CellProfiler. The DIA calculates the staining intensity and the percentage of positive cells (%PC). We found a good correlation between IRS and DIA for both SSTR2 and SSTR5 (P < .001), demonstrating the reliability of the DIA in this setting. Response to fg-SRL treatment correlated with SSTR2, but not SSTR5, expression. Somatostatin receptor subtype 2 expression predicted response to fg-SRL. In particular, the identified cut-offs were IRS ≥ 5 (area under the curve [AUC] 0.763; sensitivity 77%; specificity 83%); intensity/area ≥0.106 (AUC 0.833; sensitivity 92%; specificity 83%); and %PC-DIA ≥63.7% (AUC 0.917; sensitivity 92%; specificity 83%). The SSTR2 %PC correlated with treatment response only when evaluated using the DIA, showing a better performance of this method.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI), University of Genova, 16132 Genova, Italy.
- Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands.
- Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
ORCID-Profile: Claudia Campana, Angelo Milioto, Federico Gatto
Zitieren
APA
Campana, C., Amarù, J., Milioto, A., Nista, F., van Koetsveld, P. M., Iyer, A., Arvigo, M., Ferone, D., Hofland, L. J., & Gatto, F. (2025). Digital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone–secreting pituitary tumors. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae170
Vancouver
Campana C, Amarù J, Milioto A, Nista F, van Koetsveld PM, Iyer A, et al. Digital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone–secreting pituitary tumors. European Journal of Endocrinology. 2025. doi:10.1093/ejendo/lvae170
BibTeX
@article{Campana2025,
author = {Campana, Claudia and Amarù, Jessica and Milioto, Angelo and Nista, Federica and van Koetsveld, Peter M and Iyer, Anand and Arvigo, Marica and Ferone, Diego and Hofland, Leo J and Gatto, Federico},
title = {Digital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone–secreting pituitary tumors},
journal = {European Journal of Endocrinology},
year = {2025},
doi = {10.1093/ejendo/lvae170}
}
EUVIMED